EpiSmart™ Patents Issue

CXL Ophthalmics announced that the US Patent and Trademark Office has issued a patent covering key design features of CXLO’s EpiSmart system for epi-on corneal collagen cross-linking. Patent 9,622,911 claims an ultraviolet therapy device and its use with CXLO’s patented photosensitizer drug, comprising riboflavin and iodide ions. The key feature of the light source is the capability to cycle the light exposure in order to maintain optimal cross-linking efficiency.

CXLO was issued two US patents for its riboflavin-iodide drug (Ribostat™) earlier this year. US Patent 9,566,301 covers RiboStat’s unique composition designed to enable optimized cross-linking, and US Patent 9,555,111 covers its use with ultraviolet light therapy for corneal cross-linking.